UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Clinical cancer research, 2014-09, Vol.20 (17), p.4574-4583

2014

Volltextzugriff (PDF)

A Cytomegalovirus-Encoded Inhibitor of Apoptosis That Suppresses Caspase-8 Activation

Proceedings of the National Academy of Sciences - PNAS, 2001-07, Vol.98 (14), p.7829-7834

2001

Volltextzugriff (PDF)

Cytomegalovirus Cell Death Suppressor vMIA Blocks Bax- but Not Bak-Mediated Apoptosis by Binding and Sequestering Bax at Mitochondria

Proceedings of the National Academy of Sciences - PNAS, 2004-05, Vol.101 (21), p.7988-7993

2004

Volltextzugriff (PDF)

TSC2 S1365A mutation potently regulates CD8+ T cell function and differentiation and improves adoptive cellular cancer therapy

JCI insight, 2023-11, Vol.8 (21)

2023

Volltextzugriff (PDF)

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

Molecular cancer therapeutics, 2015-07, Vol.14 (7), p.1605-1613

2015

Volltextzugriff (PDF)

A Cytomegalovirus-Encoded Mitochondria-Localized Inhibitor of Apoptosis Structurally Unrelated to Bcl-2

Proceedings of the National Academy of Sciences - PNAS, 1999-10, Vol.96 (22), p.12536-12541

1999

Volltextzugriff (PDF)

An Anti-apoptotic Viral Protein That Recruits Bax to Mitochondria

The Journal of biological chemistry, 2004-05, Vol.279 (21), p.22605-22614

2004

Volltextzugriff (PDF)

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Neoplasia (New York, N.Y.), 2016-12, Vol.18 (12), p.775-784

2016

Volltextzugriff (PDF)

Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing

ACS medicinal chemistry letters, 2019-10, Vol.10 (10), p.1393-1399

2019

Volltextzugriff (PDF)

Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing

ACS medicinal chemistry letters, 2019-10, Vol.10 (10), p.1393-1399

2019

Volltextzugriff (PDF)

Synthesis of Highly Potent N‑10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody–Drug Conjugates (ADCs)

ACS medicinal chemistry letters, 2019-08, Vol.10 (8), p.1211-1215

2019

Volltextzugriff (PDF)

The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 4-hydroxynonenal

Oncogene, 2001-07, Vol.20 (32), p.4305-4316

2001

Volltextzugriff (PDF)

Tumor-Specific Novel Taxoid−Monoclonal Antibody Conjugates

Journal of medicinal chemistry, 2002-12, Vol.45 (26), p.5620-5623

2002

Volltextzugriff (PDF)

The Sequence and Antiapoptotic Functional Domains of the Human Cytomegalovirus UL37 Exon 1 Immediate Early Protein Are Conserved in Multiple Primary Strains

Virology (New York, N.Y.), 2001-01, Vol.279 (1), p.233-240

2001

Volltextzugriff (PDF)

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models1

Neoplasia (New York, N.Y.), 2016-12, Vol.18 (12), p.775-784

2016

Volltextzugriff (PDF)

Abstract 224: Antibody-drug conjugates (ADCs) of a new class of N-10 amino linked DNA alkylating indolino-benzodiazepines (IGNs)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.224-224

2019

Volltextzugriff (PDF)

Abstract 2890: IMGN151 - A next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2890-2890

2020

Volltextzugriff (PDF)

Abstract 667: IMGN853, a folate receptor (FR) α-targeting antibody-drug conjugate (ADC), is highly effective against xenograft models with clinically relevant levels of receptor expression

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.667-667

2014

Volltextzugriff (PDF)

Ricin A Chain Can Be Chemically Cross-linked to the Mammalian Ribosomal Proteins L9 and L10e (∗)

The Journal of biological chemistry, 1995-05, Vol.270 (21), p.12933-12940

1995

Volltextzugriff (PDF)

Abstract C61: Factors determining sensitivity of tumor cells to lorvotuzumab mertansine in vitro

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.C61-C61

2011

Volltextzugriff (PDF)

Abstract 4576: IMGN853, an anti-Folate Receptor I antibody-maytansinoid conjugate for targeted cancer therapy

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.4576-4576

2011

Volltextzugriff (PDF)

SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies

Blood, 2008-11, Vol.112 (11), p.2756-2756

2008

Volltextzugriff (PDF)

Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. A possible correlate with clinical acute phase response

The Journal of immunology (1950), 1992-01, Vol.148 (2), p.480

1992

Volltextzugriff (PDF)

Induction of apoptosis by tamoxifen-activation of a p53-estrogen receptor fusion protein expressed in E1A and T24 H-ras transformed p53-/- mouse embryo fibroblasts

Oncogene, 1996-08, Vol.13 (4), p.739-748

1996

Volltextzugriff (PDF)

Characterization of Antibody Binding to Cell Surface Antigens Using a Plasma Membrane-Bound Plate Assay

Analytical biochemistry, 1995, Vol.224 (1), p.39-50

1995

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

A Cytomegalovirus-Encoded Inhibitor of Apoptosis That Suppresses Caspase-8 Activation

Cytomegalovirus Cell Death Suppressor vMIA Blocks Bax- but Not Bak-Mediated Apoptosis by Binding and Sequestering Bax at Mitochondria

TSC2 S1365A mutation potently regulates CD8+ T cell function and differentiation and improves adoptive cellular cancer therapy

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

A Cytomegalovirus-Encoded Mitochondria-Localized Inhibitor of Apoptosis Structurally Unrelated to Bcl-2

An Anti-apoptotic Viral Protein That Recruits Bax to Mitochondria

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing

Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing

Synthesis of Highly Potent N‑10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody–Drug Conjugates (ADCs)

The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 4-hydroxynonenal

Tumor-Specific Novel Taxoid−Monoclonal Antibody Conjugates

The Sequence and Antiapoptotic Functional Domains of the Human Cytomegalovirus UL37 Exon 1 Immediate Early Protein Are Conserved in Multiple Primary Strains

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models1

Abstract 224: Antibody-drug conjugates (ADCs) of a new class of N-10 amino linked DNA alkylating indolino-benzodiazepines (IGNs)

Abstract 2890: IMGN151 - A next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression

Abstract 667: IMGN853, a folate receptor (FR) α-targeting antibody-drug conjugate (ADC), is highly effective against xenograft models with clinically relevant levels of receptor expression

Ricin A Chain Can Be Chemically Cross-linked to the Mammalian Ribosomal Proteins L9 and L10e (∗)

Abstract C61: Factors determining sensitivity of tumor cells to lorvotuzumab mertansine in vitro

Abstract 4576: IMGN853, an anti-Folate Receptor I antibody-maytansinoid conjugate for targeted cancer therapy

SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies

Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. A possible correlate with clinical acute phase response

Induction of apoptosis by tamoxifen-activation of a p53-estrogen receptor fusion protein expressed in E1A and T24 H-ras transformed p53-/- mouse embryo fibroblasts

Characterization of Antibody Binding to Cell Surface Antigens Using a Plasma Membrane-Bound Plate Assay

Suchergebnisse filtern